HilleVax (NASDAQ:HLVX – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Analyst Recommendations
This is a summary of current recommendations and price targets for HilleVax and Zura Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HilleVax | 0 | 6 | 0 | 0 | 2.00 |
| Zura Bio | 0 | 1 | 5 | 1 | 3.00 |
HilleVax presently has a consensus price target of $3.00, indicating a potential upside of 43.54%. Zura Bio has a consensus price target of $15.80, indicating a potential upside of 631.48%. Given Zura Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than HilleVax.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HilleVax | N/A | N/A | -$123.57 million | ($3.10) | -0.67 |
| Zura Bio | N/A | N/A | -$69.24 million | N/A | N/A |
Institutional & Insider Ownership
86.4% of HilleVax shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 71.1% of HilleVax shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares HilleVax and Zura Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HilleVax | N/A | -67.27% | -51.99% |
| Zura Bio | N/A | -37.36% | -29.81% |
Risk & Volatility
HilleVax has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.
Summary
Zura Bio beats HilleVax on 7 of the 10 factors compared between the two stocks.
About HilleVax
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.
